SOFIA DIANA MERAJVER

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer
    Basil Hassouneh
    Department of Otolaryngology Head and Neck Surgery, University of Michigan, 1500 East Medical Centre Drive, 1904 Taubman Center, Ann Arbor, MI 48109, USA
    Mol Cancer Ther 6:1039-45. 2007
  2. pmc Healthcare access and mammography screening in Michigan: a multilevel cross-sectional study
    Tomi F Akinyemiju
    Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
    Int J Equity Health 11:16. 2012
  3. pmc Using a state cancer registry to recruit young breast cancer survivors and high-risk relatives: protocol of a randomized trial testing the efficacy of a targeted versus a tailored intervention to increase breast cancer screening
    Maria C Katapodi
    University of Michigan School of Nursing, 400 N, Ingalls Building, Room 2158, Ann Arbor, MI 48109, USA
    BMC Cancer 13:97. 2013
  4. pmc Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1
    Min Lin
    Division of Hematology Oncology, Department of Internal Medicine, The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Mol Cancer 4:21. 2005
  5. pmc WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res 6:R110-5. 2004
  6. pmc Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells
    Yanhong Zhang
    Department of Pathology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
    Breast Cancer Res 7:R1080-9. 2005
  7. ncbi request reprint Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience
    S D Merajver
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 0680, USA
    J Clin Oncol 15:2873-81. 1997
  8. ncbi request reprint Breast cancer risk assessment: a guide for clinicians using the NCCN Breast Cancer Risk Reduction Guidelines
    Sofia D Merajver
    Breast and Ovarian Cancer Risk Evaluation Clinic, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Natl Compr Canc Netw 1:297-301. 2003
  9. pmc Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivity
    Michelle L Wynn
    Center for Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA
    BMC Syst Biol 5:156. 2011
  10. ncbi request reprint Multifaceted role of Rho proteins in angiogenesis
    Sofia D Merajver
    Breast and Ovarian Cancer Risk Evaluation Program, University of Michigan Comprehensive Cancer Center, 7217 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0948, USA
    J Mammary Gland Biol Neoplasia 10:291-8. 2005

Collaborators

Detail Information

Publications62

  1. ncbi request reprint Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer
    Basil Hassouneh
    Department of Otolaryngology Head and Neck Surgery, University of Michigan, 1500 East Medical Centre Drive, 1904 Taubman Center, Ann Arbor, MI 48109, USA
    Mol Cancer Ther 6:1039-45. 2007
    ..Taken together, these results show that tetrathiomolybdate can act long-term as a suppressor of vascularity and inhibit the growth of metastasis in this model of HNSCC...
  2. pmc Healthcare access and mammography screening in Michigan: a multilevel cross-sectional study
    Tomi F Akinyemiju
    Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
    Int J Equity Health 11:16. 2012
    ..Breast cancer screening rates have increased over time in the United States. However actual screening rates appear to be lower among black women compared with white women...
  3. pmc Using a state cancer registry to recruit young breast cancer survivors and high-risk relatives: protocol of a randomized trial testing the efficacy of a targeted versus a tailored intervention to increase breast cancer screening
    Maria C Katapodi
    University of Michigan School of Nursing, 400 N, Ingalls Building, Room 2158, Ann Arbor, MI 48109, USA
    BMC Cancer 13:97. 2013
    ....
  4. pmc Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1
    Min Lin
    Division of Hematology Oncology, Department of Internal Medicine, The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Mol Cancer 4:21. 2005
    ..RhoC GTPase is overexpressed in aggressive cancers that metastasize and is the predominant GTPase in PC. Like several GTPases, RhoC contains a putative cav-1 binding motif...
  5. pmc WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res 6:R110-5. 2004
    ..We have demonstrated that WISP3 has tumor growth and angiogenesis inhibitory functions in IBC. We hypothesized that RhoC and WISP3 cooperate in the development of IBC...
  6. pmc Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells
    Yanhong Zhang
    Department of Pathology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
    Breast Cancer Res 7:R1080-9. 2005
    ..We hypothesized that inhibition of CCN6 might result in the loss of a growth regulatory function that protects mammary epithelial cells from the tumorigenic effects of growth factors, particularly IGF-1...
  7. ncbi request reprint Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience
    S D Merajver
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 0680, USA
    J Clin Oncol 15:2873-81. 1997
    ..To determine whether breast conservation and prolonged neoadjuvant chemotherapy have efficacy in locally advanced breast cancer (LABC), as measured by survival and rate of breast conservation...
  8. ncbi request reprint Breast cancer risk assessment: a guide for clinicians using the NCCN Breast Cancer Risk Reduction Guidelines
    Sofia D Merajver
    Breast and Ovarian Cancer Risk Evaluation Clinic, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Natl Compr Canc Netw 1:297-301. 2003
    ..This article summarizes these models and gives brief guidelines about which model may be preferable given a specific family history...
  9. pmc Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivity
    Michelle L Wynn
    Center for Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA
    BMC Syst Biol 5:156. 2011
    ..We hypothesize that targeted therapies such as kinase inhibitors can produce off-target effects as a consequence of retroactivity alone...
  10. ncbi request reprint Multifaceted role of Rho proteins in angiogenesis
    Sofia D Merajver
    Breast and Ovarian Cancer Risk Evaluation Program, University of Michigan Comprehensive Cancer Center, 7217 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0948, USA
    J Mammary Gland Biol Neoplasia 10:291-8. 2005
    ..Concordant with their roles in multiple processes of cellular control, the Rho proteins have been shown to be involved in tumor growth, progression, metastasis, and now angiogenesis...
  11. ncbi request reprint Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer
    Kenneth L van Golen
    Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109 0948, USA
    Clin Exp Metastasis 19:301-11. 2002
    ..We found that activation of the MAPK pathway was responsible for motility, invasion and production of angiogenic factors. In contrast, growth under anchorage independent conditions was dependent on the PI3K pathway...
  12. ncbi request reprint Modulation of angiogenesis for cancer prevention: strategies based on antioxidants and copper deficiency
    Gazala N Khan
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Curr Pharm Des 13:3584-90. 2007
    ..We use these strategies as paradigms of how to make progress in this difficult but important area of translational research...
  13. ncbi request reprint Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade
    Quintin Pan
    Department of Internal Medicine, Division of Hematology and Oncology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Mol Cancer Res 1:701-6. 2003
    ..Taken together, these results strongly support that suppression of NFkappaB is the major mechanism used by TM to inhibit angiogenesis and metastasis...
  14. ncbi request reprint Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis
    Quintin Pan
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Res 62:4854-9. 2002
    ..Our study suggests that a major mechanism of the antiangiogenic effect of copper deficiency induced by TM is suppression of NFkappaB, contributing to a global inhibition of NFkappaB-mediated transcription of proangiogenic factors...
  15. ncbi request reprint RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, 48109, USA
    Clin Cancer Res 12:4485-90. 2006
    ..This study evaluated the expression of RhoC in head and neck carcinoma and investigated the prognostic use of this marker on a large cohort of previously untreated patients with SCCHN...
  16. pmc Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1
    Wei Huang
    Department of Pathology, University of Michigan Medical School, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0605, USA
    Am J Pathol 172:893-904. 2008
    ..Together, our results lead to a new hypothesis that Snail and ZEB1 are downstream of CCN6 and play a critical role in CCN6-mediated regulation of E-cadherin in breast cancer...
  17. ncbi request reprint RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells
    Mei Wu
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109 0948, USA
    Breast Cancer Res Treat 84:3-12. 2004
    ..We have further verified by quantitative RT-PCR that genes involved in cell proliferation, invasion/adhesion, and angiogenesis were modulated by RhoC. This work suggests strong candidates for the downstream oncogenic functions of RhoC...
  18. pmc WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48108, USA
    Neoplasia 6:179-85. 2004
    ....
  19. pmc Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer
    LiWei Bao
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer Res 69:5829-34. 2009
    ..02) retards the growth of UMSCC1 xenografts in nude mice. Our work indicates that the bifunctional HN1-PKCepsilon inhibitory peptide represents a promising novel therapeutic strategy for HNSCC...
  20. ncbi request reprint Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor
    Kenneth L van Golen
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Mol Cancer Ther 1:575-83. 2002
    ..These data provide direct evidence that FTIs may find use in the clinic when directed against RhoC-overexpressing tumors and suggest appropriate biological markers to evaluate during FTI treatment...
  21. ncbi request reprint Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers
    Mei Wu
    Department of Internal Medicine, Division of Hematology and Oncology and Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan
    Cancer 116:2768-82. 2010
    ..The 2 closely related small GTPases, RHOC and RHOA, are involved in mammary gland carcinogenesis; however, their specific roles in determining cancer cell adhesion and invasion have not been elucidated...
  22. ncbi request reprint Rho proteins and cell-matrix interactions in cancer
    Mei Wu
    Division of Hematology and Oncology and Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, Mich 48109 0948, USA
    Cells Tissues Organs 185:100-3. 2007
    ..In this mini-review, we discuss the functions of the Rho proteins and their relationship with other signaling pathways in matrix remodeling and integrin signaling of highly motile and invasive cancer cells...
  23. ncbi request reprint Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy
    Mei Wu
    Department of Internal Medicine, Division of Hematology and Oncology and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109 0948, USA
    Breast Dis 22:25-34. 2005
    ..In this review, we discuss the current advances in understanding the genetic determinants of IBC with emphasis on their present and potential applications to diagnosis, prognosis, and treatment...
  24. pmc Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients
    An Chi Lo
    Department of Epidemiology, University of Michigan School of Public Health, 109 Observatory Street, Ann Arbor, MI 48109, USA
    Breast Cancer Res Treat 112:141-7. 2008
    ..A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors...
  25. ncbi request reprint WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, Univeristy of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res 6:R110-5. 2004
    ..We have demonstrated that WISP3 has tumor growth and angiogenesis inhibitory functions in IBC. We proposed that RhoC and WISP3 cooperate in the development of IBC...
  26. ncbi request reprint Molecular determinants of the inflammatory breast cancer phenotype
    Nathan W Houchens
    Department of Internal Medicine, University of Michigan, Health System, USA
    Oncology (Williston Park) 22:1556-61; discussion 1561, 1565-8, 1576. 2008
    ....
  27. ncbi request reprint CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling
    CHRIS R EVELYN
    Department of Pharmacology, University of Michigan Medical Center, 1301 MSRB III, Room 2220D, 1150 West Medical Center Drive, Ann Arbor, MI 48109 0632, USA
    Mol Cancer Ther 6:2249-60. 2007
    ..Thus, based on its profile, CCG-1423 is a promising lead compound for the development of novel pharmacologic tools to disrupt transcriptional responses of the Rho pathway in cancer...
  28. ncbi request reprint CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer
    Celina G Kleer
    Department of Pathology, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Mich 48109, USA
    Cells Tissues Organs 185:95-9. 2007
    ..This review will focus on the current knowledge regarding the function of CCN6 in breast cancer with special emphasis on the emerging role of CCN6 as a regulator of the epithelial phenotype and E-cadherin expression in the breast...
  29. pmc Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt
    Subhojit Dey
    Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, MI, 48109, USA
    Breast Cancer Res Treat 120:149-60. 2010
    ..ER-incidence rate was 2-3 times (IRR = 1.86, 95% CI = 2.38, 1.45) higher in urban areas than in rural areas. Our findings indicate that urban women may probably have a higher exposure to xenoestrogens...
  30. ncbi request reprint From in vitro to in silico and back again: using biological and mathematical synergy to decipher breast cancer cell motility
    Devin T Rosenthal
    University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Conf Proc IEEE Eng Med Biol Soc 2010:3261-4. 2010
    ..Fusing biology and mathematics as presented here represents a new direction for biomedical research in which advances in each field synergistically drive discoveries in the other...
  31. pmc Urban-rural differences in breast cancer incidence in Egypt (1999-2006)
    Subhojit Dey
    Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, MI 48109, USA
    Breast 19:417-23. 2010
    ..To describe urban-rural differences in breast cancer incidence in Gharbiah, Egypt and to investigate if these differences could be explained by known risk factors of breast cancer...
  32. pmc Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy
    Lori J Pierce
    Department of Radiation Oncology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive Room 4308, Ann Arbor, MI 48109, USA
    Breast Cancer Res Treat 121:389-98. 2010
    ..However, women undergoing BCT have an elevated risk of a second in-breast event that is significantly reduced in the presence of chemotherapy. Contralateral breast cancer events are very common...
  33. pmc BRCA1 regulates human mammary stem/progenitor cell fate
    Suling Liu
    Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 105:1680-5. 2008
    ..Because BRCA1 also plays a role in DNA repair, our work suggests that loss of BRCA1 may result in the accumulation of genetically unstable breast stem cells, providing prime targets for further carcinogenic events...
  34. ncbi request reprint Pomegranate fruit extract impairs invasion and motility in human breast cancer
    Gazala N Khan
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Integr Cancer Ther 8:242-53. 2009
    ..Because nuclear transcription factor-kB (NF-kB) is known to regulate cell survival, proliferation, tumorigenesis, and inflammation, it was postulated that PFEs may exert anticancer effects at least in part by modulating NF-kB activity...
  35. ncbi request reprint Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma
    Quintin Pan
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, MI 48109, USA
    Cancer Res 66:9379-84. 2006
    ..Our study shows, for the first time, that PKC epsilon is involved in a coordinated regulation of RhoA and RhoC activation, possibly through direct post-translational phosphorylation...
  36. pmc Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability
    Celina G Kleer
    Department of Pathology, Division of Hematology and Oncology, 2G332 University Hospital, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0054, USA
    Am J Pathol 160:579-84. 2002
    ..RhoC is specifically expressed in invasive breast carcinomas capable of metastasizing, and it may be clinically useful in patients with tumors smaller than 1 cm to guide treatment...
  37. pmc Radiotherapy and antiangiogenic TM in lung cancer
    Mohamed K Khan
    Department of Radiation Oncology, The University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
    Neoplasia 4:164-70. 2002
    ..We also show that their therapeutic effects are additive, with no additional toxicity. We show that TM has no significant cytotoxicity in vitro against LLHM tumor cells, further supporting the antiangiogenic mechanism for its action...
  38. ncbi request reprint WISP3 is a novel tumor suppressor gene of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0054, USA
    Oncogene 21:3172-80. 2002
    ..Our data demonstrate that WISP3 acts as a tumor suppressor gene in the breast. Loss of WISP3 expression contributes to the phenotype of IBC by regulating tumor cell growth, invasion and angiogenesis...
  39. pmc Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma
    Kenneth L van Golen
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0948, USA
    Neoplasia 4:373-9. 2002
    ..Improved survival, fewer metastatic lesions, and excellent tolerability were observed with the combination therapy...
  40. ncbi request reprint Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer
    Bruce G Redman
    Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor 48109 0948, USA
    Clin Cancer Res 9:1666-72. 2003
    ..Tetrathiomolybdate (TM), a copper-lowering agent, has been shown in preclinical murine tumor models to be antiangiogenic. We evaluated the antitumor activity of TM in patients with advanced kidney cancer in a Phase II trial...
  41. ncbi request reprint Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma
    Quintin Pan
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Mol Cancer Ther 2:617-22. 2003
    ..4 +/- 14.3% greater than that in doxorubicin-treated mice. These results suggest that TM may enhance the rate of pathological complete response when used in combination with an anthracycline in neoadjuvant therapy of breast carcinoma...
  42. ncbi request reprint Detection of Epstein-Barr virus in rapidly growing fibroadenomas of the breast in immunosuppressed hosts
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
    Mod Pathol 15:759-64. 2002
    ..This is the first study suggesting a role for EBV in the pathogenesis of fibroadenomas...
  43. ncbi request reprint Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review
    George J Brewer
    Department of Human Genetics and Department of Internal Medicine, University of Michigan Medical School, 4009 Buhl Building, Ann Arbor, MI 48109 0618, USA
    Integr Cancer Ther 1:327-37. 2002
    ..The authors speculate that the copper level is a primitive angiogenesis and growth-signaling regulator that has been retained throughout evolution...
  44. ncbi request reprint Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population
    Emily A Peterson
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Cancer Epidemiol Biomarkers Prev 11:79-87. 2002
    ..Our research provides evidence that these fears may be discrepant with the actual experiences of patients in high-risk clinics...
  45. ncbi request reprint Control of copper status for cancer therapy
    Vicki L Goodman
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Curr Cancer Drug Targets 5:543-9. 2005
    ..Promising results from in vitro experiments, in pre-clinical animal models, and in a phase I clinical trial have led to several phase II trials of TM in patients with advanced cancers...
  46. ncbi request reprint RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast
    Celina G Kleer
    Department of Pathology and Internal Medicine, University of Michigan, Ann Arbour, MI 48109 0054, USA
    Breast Cancer Res Treat 93:101-10. 2005
    ..We hypothesized that RhoC expression would identify aggressive, non-IBC tumors breast cancer patients at any stage with worse outcomes defined as recurrence and/or metastasis...
  47. ncbi request reprint The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck
    Theodoros N Teknos
    Department of Otolaryngology Head and Neck Surgery, University of Michigan Medical Center, Ann Arbor, MI 48103, USA
    Arch Otolaryngol Head Neck Surg 131:204-11. 2005
    ..To assess the effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth rate in human squamous cell carcinoma (SCC)...
  48. ncbi request reprint Genetic counseling for BRCA1/2: a randomized controlled trial of two strategies to facilitate the education and counseling process
    Catharine Wang
    Department of Health Behavior and Health Education, University of Michigan, School of Public Health, Ann Arbor, MI 48104, USA
    Am J Med Genet A 134:66-73. 2005
    ..No interaction effects of the two intervention arms were found. The study results support the importance of both strategies as valuable supplements to clinical BRCA1/2 counseling...
  49. ncbi request reprint Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer
    Lori J Pierce
    Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI 48109 0010, USA
    J Clin Oncol 24:2437-43. 2006
    ..We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mutation carriers with breast cancer versus that of matched sporadic controls...
  50. ncbi request reprint Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy
    Quintin Pan
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
    Cancer Res 65:8366-71. 2005
    ..Taken together, these results revealed that PKC epsilon plays a critical and causative role in promoting an aggressive metastatic breast cancer phenotype and as a target for anticancer therapy...
  51. ncbi request reprint Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma
    Benjamin Marcus
    Department of Otolaryngology Head and Neck Surgery, University of Michigan Medical Center, Ann Arbor, Michigan 48103, USA
    Cancer 101:2779-87. 2004
    ..The authors hypothesized that tumor-associated macrophages contribute to HNSCC aggressiveness, and the objective of the current study was to prove this hypothesis using mRNA expression analysis and a large cohort of clinical specimens...
  52. ncbi request reprint Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model
    Claudell Cox
    Department of Otolaryngology Head and Neck Surgery, University of Michigan Health System, Ann Arbor, 48109, USA
    Arch Otolaryngol Head Neck Surg 129:781-5. 2003
    ..To determine whether long-term therapy with tetrathiomolybdate suppresses tumor growth in an animal model...
  53. doi request reprint One-hit effects and cancer
    Maria D Iniesta
    Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, 48109, USA
    Cancer Prev Res (Phila) 3:12-5. 2010
    ..The work of Bellacosa et al. is an important step toward discerning which pathways may be altered when one BRCA allele is inactivated...
  54. ncbi request reprint Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues
    Lei Ding
    Department of Pathology, University of Michigan Medical School, Ann Arbor 48109, USA
    Cancer Res 66:4095-9. 2006
    ..We identify EZH2 as a potential marker for detecting preneoplastic lesions of the breast in vivo and as a possible target for preventative intervention...
  55. ncbi request reprint Inflammatory breast cancer: what are the treatment options?
    Maria D Iniesta
    University of Michigan, Comprehensive Cancer Center, Department of Internal Medicine, Ann Arbor, 48109 0948, USA
    Expert Opin Pharmacother 10:2987-97. 2009
    ..Palpable axillary lymphadenopathy is appreciated on the right only. The left breast is uninvolved. The physician is concerned that she may have inflammatory breast cancer...
  56. pmc Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia
    Xin Li
    Department of Pathology, University of Michigan Medical School, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Am J Pathol 175:1246-54. 2009
    ....
  57. pmc Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients
    An Chi Lo
    Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
    Breast 18:55-9. 2009
    ..Future studies should focus on relating epidemiologic factors to molecular features of IBC in this population...
  58. doi request reprint Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world
    Subhojit Dey
    Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, MI 48109, USA
    Med Hypotheses 72:652-6. 2009
    ....
  59. ncbi request reprint Genetic determinants of aggressive breast cancer
    Alejandra C Ventura
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan 48109 0948, USA
    Annu Rev Med 59:199-212. 2008
    ..Using IBC as an example, we describe in detail the approaches to identify the genes that are responsible for-and not merely associated with-this disease...
  60. doi request reprint Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America
    Maria D Iniesta
    Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cancer Genet Cytogenet 202:136-40. 2010
    ....
  61. ncbi request reprint Metastatic dedifferentiated chordoma with elevated beta-hCG: a case report
    Hidayatullah G Munshi
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor 48109 0948, USA
    Am J Clin Oncol 25:274-6. 2002
    ..However, chemotherapy may play a useful role in the management of systemic disease in patients with dedifferentiated chordoma...
  62. doi request reprint On the role of cell signaling models in cancer research
    Alejandra C Ventura
    University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Res 69:400-2. 2009
    ....

Research Grants9

  1. PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE
    Sofia Merajver; Fiscal Year: 2007
    ..Understand whether TM regulates uPAR expression and erk signaling in her2 and wnt transgenic tumors. ..
  2. PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE
    Sofia Merajver; Fiscal Year: 1999
    ..By defining the molecular basis of TM's inhibition of angiogenesis, this work will help tailor the clinical application of TM in cancer. ..
  3. PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE
    Sofia Merajver; Fiscal Year: 2000
    ..By defining the molecular basis of TM's inhibition of angiogenesis, this work will help tailor the clinical application of TM in cancer. ..
  4. PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE
    Sofia Merajver; Fiscal Year: 2001
    ..By defining the molecular basis of TM's inhibition of angiogenesis, this work will help tailor the clinical application of TM in cancer. ..
  5. PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE
    Sofia Merajver; Fiscal Year: 2002
    ..By defining the molecular basis of TM's inhibition of angiogenesis, this work will help tailor the clinical application of TM in cancer. ..
  6. PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE
    Sofia Merajver; Fiscal Year: 2003
    ..Understand whether TM regulates uPAR expression and erk signaling in her2 and wnt transgenic tumors. ..
  7. PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE
    Sofia Merajver; Fiscal Year: 2004
    ..Understand whether TM regulates uPAR expression and erk signaling in her2 and wnt transgenic tumors. ..
  8. PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE
    Sofia Merajver; Fiscal Year: 2005
    ..Understand whether TM regulates uPAR expression and erk signaling in her2 and wnt transgenic tumors. ..
  9. PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE
    Sofia Merajver; Fiscal Year: 2006
    ..Understand whether TM regulates uPAR expression and erk signaling in her2 and wnt transgenic tumors. ..